A phase 2a Safety and Efficacy study of TAR-0520 gel in prevention of taxanes-induced peripheral neuropathy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521674-33-00

Acronym

TARIAN 014

Enrollment

Registered

2025-06-27

Start date

2025-11-05

Completion date

Unknown

Last updated

2025-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Taxanes-induced peripheral neuropathy

Brief summary

Incidence of Adverse Events, Adverse Events of Special Interest and Serious Adverse Events

Detailed description

Incidence and severity of NCI-CTCAE (Nervous system disorders) grading by oncologist

Interventions

DRUGTAR-0520 Gel

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of Adverse Events, Adverse Events of Special Interest and Serious Adverse Events	—

Secondary

Measure	Time frame
Incidence and severity of NCI-CTCAE (Nervous system disorders) grading by oncologist	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026